Table 5.
Multivariate analysis of independent prognostic factors for DSS and OS in patients with invasive carcinoma of the breast (pooled NEC and IMC-NOS)
| Group |
DSS |
|
OS |
|
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age, years (>60 vs ≤60) |
1.14 (1.13-1.16) |
<0.0001 |
2.62 (2.60-2.65) |
<0.0001 |
| Tumor size, mm (>20 vs ≤20) |
1.65 (1.64-1.66) |
<0.0001 |
1.34 (1.33-1.35) |
<0.0001 |
| LN (positive vs negative) |
1.98 (1.97-2.00) |
<0.0001 |
1.64 (1.63-1.65) |
<0.0001 |
| Grade (III vs I, II) |
1.26 (1.25-1.27) |
<0.0001 |
1.12 (1.11-1.13) |
<0.0001 |
| ER status (positive vs negative) |
0.82 (0.81-0.83) |
<0.0001 |
0.90 (0.89-0.91) |
<0.0001 |
| PR status (positive vs negative) |
0.88 (0.87-0.89) |
<0.0001 |
0.93 (0.92-0.94) |
<0.0001 |
| Neuroendocrine (positive vs negative) |
1.80 (1.36-2.37) |
<0.0001 |
1.84 (1.50-2.26) |
<0.0001 |
| Radiation (yes vs no) |
0.90 (0.89-0.91) |
<0.0001 |
0.75 (0.74-0.76) |
<0.0001 |
| Surgery (yes vs no) | 0.44 (0.43-0.45) | <0.0001 | 0.45 (0.46-0.47) | <0.0001 |
DSS, disease-specific survival; OS, overall survival; NEC; neuroendocrine carcinoma; IMC-NOS, invasive mammary carcinoma, not otherwise specified; HR, hazard ratio; CI, confidence interval; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor.